Head and neck squamous cell carcinoma.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR.
Nat Rev Dis Primers. 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3.
Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma.
Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A.
Med Sci (Basel). 2023 Jun 13;11(2):42. doi: 10.3390/medsci11020042.
Target volume selection and delineation (T and N) for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma.
Grégoire V, Grau C, Lapeyre M, Maingon P.
Oral Oncol. 2018 Dec;87:131-137. doi: 10.1016/j.oraloncology.2018.10.034. Epub 2018 Nov 3.
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B, Young RJ, Rischin D.
Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240. doi: 10.1016/j.semcancer.2018.01.008. Epub 2018 Jan 31.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL.
J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E.
Lancet Oncol. 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3.
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J.
Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28.
First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE-048.
Oridate N, Takahashi S, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Lerman N, Tahara M.
Int J Clin Oncol. 2024 Dec;29(12):1825-1839. doi: 10.1007/s10147-024-02632-x. Epub 2024 Oct 9.
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, Dechaphunkul A, Dinis J, Guo Y, Masuda M, Hsieh CY, Ghi MG, Vaz de Melo Sette C, Harrington K, Tahara M, Saba NF, Lau A, Jiang T, Yan Y, Ballinger M, Kaul M, Matheny C, Cuchelkar V, Wong DJ.
JAMA. 2025 May 13;333(18):1599-1607. doi: 10.1001/jama.2025.1483.
Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer.
Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP, Freedman ND, Gapstur SM, Pei Z.
JAMA Oncol. 2018 Mar 1;4(3):358-365. doi: 10.1001/jamaoncol.2017.4777.
